Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
About this article
Tevogen Bio Holdings Inc. has made progress on its PredicTcell™ training, initiated commercial readiness, and launched an internal application portal as of April 27, 2026.
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal PRESS RELEASE GlobeNewswire Apr. 27, 2026, 11:50 AM WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including the near completion of its PredicTcell™ training algorithm and early steps toward commercial readiness.PredicTcell™, Tevogen.AI’s proprietary machine learning model designed to identify immunologically active peptides, is approaching the final stages of its training phase. The model has been trained on one of the industry’s largest curated peptide datasets, with feature expansion now exceeding 180 parameters, contributing to an approximate 10% improvement in precision.As development progresses, the Company has begun evaluating potential co-development partnerships to support broader application of the platform. These efforts are grounded in addressing a fundamental challenge in drug development, high-confidence target identification, which today often requires significant wet lab validation. By leveraging advanced predictive modeling, Tevogen.AI aims to reduce development timelines, material costs, and overall experimental burden.To support this transition, Tevogen.AI has developed an initial version of an internal application and portal designed to serve the PredicTcell™ model in a sc...
